The New York State Medical Marijuana Program updated its website today and revealed that it will be registering five more organizations. The program’s initial licenses were awarded to Bloomfield Industries (recently acquired by MedMen), Columbia Care, Etain, PharmaCann and Vireo Health. The program has been slow to start, with just 867 practitioners and 14,045 patients that have registered thus far. While the addition of five new organizations could oversupply the market, the state has recently made several changes that could broaden the base of patients, including adding chronic pain as a qualifying condition and also allowing nurse practitioners and physician assistants to certify patients. Here is the update to the program’s website:
Pursuant to the recommendation of the Medical Marijuana Program to register five additional organizations over the next two years to better serve patients throughout New York State, the Department has contacted the next five highest-scoring organizations:
- New York Canna, Inc.;
- Fiorello Pharmaceuticals, Inc.;
- Valley Agriceuticals, LLC;
- Citiva Medical LLC; and
- PalliaTech NY, LLC.
The Department is undertaking a phased-in approach to ensure their smooth integration into the industry. The approach includes performing due diligence, verifying their current financial stability and capitalization, and ensuring their overall suitability to participate in the Medical Marijuana Program in a manner that promotes public health and protects public safety. No other organizations or entities are currently under consideration.
The New York website lists the original scores for all of the applicants from 2015 and links to the full applications (with some redactions), including those of the 5 new organizations that it named today.
